Pacific Biosciences of California (PACB) and Invitae (NVTA) have modified their existing development and commercialization agreement, according to a...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Pacific Biosciences (PACB) said Monday it has entered into a collaboration with genome analysis company iLAC and Robotic Biology Institute to develop...
...
| Address | 1305 O'Brien Drive Menlo Park, California 94025 |
| Phone | +1.650.521.8000 |
| Number of Employees | 401 |
| Recent SEC Filing | 06/30/2022 8-K |
| President, Chief Executive Officer & Director | Christian O. Henry |
| Chief Operating Officer | Mark David van Oene |
| Chief Financial Officer | Susan G. Kim |
| Chief Technology Officer | Stephen W. Turner |
| Price Open | $4.47 |
| Previous Close | $4.42 |
| 52 Week Range | $3.85 - 35.58 |
| Market Capitalization | $1.0 B |
| Shares Outstanding | 224.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/02/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.71 |
| Beta vs. S&P 500 | N/A |
| Revenue | $78.6 M |
| Net Profit Margin | -130.14% |
| Return on Equity | -26.71% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
